EDEN PRAIRIE, Minn., Feb. 08, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will host a conference call and webcast on February 13, 2024 at 4:30 PM Eastern Time to discuss financial results for its first quarter of fiscal year 2024 ended December 31, 2023, and provide a corporate update.
Conference Call and Webcast Information:
Tuesday, February 13, 2024 – 4:30 PM Eastern Time
Participant Dial-In:
888-506-0062 / +1 973-528-0011
Access Code:
540724
Live Webcast:
Join here.
Phone Replay:
877-481-4010/ +1 919-882-2331
Available through February 27, 2024
Webcast Replay:
Available for 12 months
About NeuroOne
NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit nmtc1.com.
Contact:
800-631-4030
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$0.76 |
Daily Volume: | 89,171 |
Market Cap: | US$23.350M |
October 31, 2024 September 10, 2024 September 05, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB